Effect of Angiotensin II on Macrophage Functions

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 1983 Mar 1

PMID 6826203

Citations 11

Authors

G Foris

B Dezso

G A Medgyesi

G Fust

Affiliations

Soon will be listed here.

Abstract

Angiotensin II (At II) has been shown to inhibit in vitro the IgG2a-mediated rosette formation of 51Cr-sheep red blood cells (SRBC) by provoked peritoneal macrophages (PM) at 10(-5)-10(-6) M concentrations. The decreased rosette formation was associated with an increased phagocytosis. It was found that the enhanced rosette formation at 10(-7) M hormone concentration was followed by diminished phagocytosis via Fc gamma receptors (R). Processes mediated through Fc microR were affected only after incubation with 10(-5) M of At II. The attachment and subsequent phagocytosis through C3bR was markedly enhanced by At II in a dose-dependent way. Thus, the relative phagocytosis (RP) through both FcRs was significantly enhanced by 10(-5), i.e. by 10(-5)-10(-6) M of At II, but lowered at 10(-7) M hormone concentration. In addition, there was no RP enhancing effect of At II after preincubation with 10(-5) M of indomethacin (IM), indicating the significance of prostaglandins (PG) in the hormone effect. The medium containing 5 mM of EGTA diminished both the RP enhancing and inhibiting effects of At II. The RP mediated by C3b was not affected by At II, IM or EGTA. The intracellular killing capability, measured by chromium release from Candida albicans, was not altered or even slightly diminished after At II treatment of PMs.

Citing Articles

Role of angiotensin II in cellular entry and replication of dengue virus.

Pedreanez A, Carrero Y, Vargas R, Hernandez-Fonseca J, Mosquera J Arch Virol. 2024; 169(6):121.

PMID: 38753119 DOI: 10.1007/s00705-024-06040-4.

Drug Therapy for Heart Valve Diseases.

Borer J, Sharma A Circulation. 2015; 132(11):1038-45.

PMID: 26371236 PMC: 4582425. DOI: 10.1161/CIRCULATIONAHA.115.016006.

Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases.

He A, Shi G Curr Pharm Des. 2012; 19(6):1114-25.

PMID: 23016684 PMC: 3921624. DOI: 10.2174/1381612811319060012.

Are angiotensin converting enzyme inhibitors beneficial in patients with aortic stenosis?.

Shavelle D Heart. 2005; 91(10):1257-9.

PMID: 16162605 PMC: 1769118. DOI: 10.1136/hrt.2004.056614.

Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis.

Nishida M, Fujinaka H, Matsusaka T, Price J, Kon V, Fogo A J Clin Invest. 2002; 110(12):1859-68.

PMID: 12488436 PMC: 151648. DOI: 10.1172/JCI15045.

References

Baudouin-Legros M, Meyer P . Effects of angiotensin, catecholamines and cyclic AMP on calcium storage in aortic microsomes. Br J Pharmacol. 1973; 47(2):377-85. PMC: 1776538. DOI: 10.1111/j.1476-5381.1973.tb08335.x. View

Inoue K, SMULYAN H, Mucha E, EICH R . Enhancement of the inotropic action of glucagon by small concentration of angiotensin. Jpn Heart J. 1973; 14(3):239-48. DOI: 10.1536/ihj.14.239. View

Bolton A, Hunter W . The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Biochem J. 1973; 133(3):529-39. PMC: 1177731. DOI: 10.1042/bj1330529. View

Gimbrone Jr M, Alexander R . Angiotensin II stimulation of prostaglandin production in cultured human vascular endothelium. Science. 1975; 189(4198):219-20. DOI: 10.1126/science.1138377. View

Tack B, Prahl J . Third component of human complement: purification from plasma and physicochemical characterization. Biochemistry. 1976; 15(20):4513-21. DOI: 10.1021/bi00665a028. View

Yamamura M, Boler J, Valdimarsson H . A chromium release assay for phagocytic killing of Candida albicans. J Immunol Methods. 1976; 13(3-4):227-33. DOI: 10.1016/0022-1759(76)90069-7. View

Razin E, BAUMINGER S, Globerson A . Effect of prostaglandins on phagocytosis of sheep erythrocytes by mouse peritoneal macrophages. J Reticuloendothel Soc. 1978; 23(4):237-42. View

Shimada K, Yazaki Y . Binding sites for angiotensin II in human mononuclear leucocytes. J Biochem. 1978; 84(4):1013-5. DOI: 10.1093/oxfordjournals.jbchem.a132183. View

Wahl S, Wahl L, McCarthy J, CHEDID L, Mergenhagen S . Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide. J Immunol. 1979; 122(6):2226-31. View

10.

Newman S, JOHNSTON Jr R . Role of binding through C3b and IgG in polymorphonuclear neutrophil function: studies with trypsin-generated C3b. J Immunol. 1979; 123(4):1839-46. View

11.

Griffin J, Griffin Jr F . Augmentation of macrophage complement receptor function in vitro. I. Characterization of the cellular interactions required for the generation of a T-lymphocyte product that enhances macrophage complement receptor function. J Exp Med. 1979; 150(3):653-75. PMC: 2185661. DOI: 10.1084/jem.150.3.653. View

12.

Vogel S, Rosenstreich D . Defective Fc receptor-mediated phagocytosis in C3H/HeJ macrophages. I. Correction by lymphokine-induced stimulation. J Immunol. 1979; 123(6):2842-50. View

13.

Gemsa D, Kramer W, Brenner M, TILL G, Resch K . Induction of prostaglandin E release from macrophages by colchicine. J Immunol. 1980; 124(1):376-80. View

14.

Vogel S, Weedon L, Oppenheim J, Rosenstreich D . Defective Fc-mediated phagocytosis in C3H/HeJ macrophages. II. Correction by cAMP agonists. J Immunol. 1981; 126(2):441-5. View

15.

Cummings N, Pabst M, JOHNSTON Jr R . Activation of macrophages for enhanced release of superoxide anion and greater killing of Candida albicans by injection of muramyl dipeptide. J Exp Med. 1980; 152(6):1659-69. PMC: 2186025. DOI: 10.1084/jem.152.6.1659. View

16.

Goetzl E, Klickstein L, Watt K, Wintroub B . The preferential human mononuclear leukocyte chemotactic activity of the substituent tetrapeptides of angiotensin II. Biochem Biophys Res Commun. 1980; 97(3):1097-102. DOI: 10.1016/0006-291x(80)91488-6. View

17.

Medgyesi G, Miklos K, Kulics J, Fust G, Gergely J, Bazin H . Classes and subclasses of rat antibodies: reaction with the antigen and interaction of the complex with the complement system. Immunology. 1981; 43(1):171-6. PMC: 1555175. View